Navigation Links
Orexigen® Therapeutics Presents Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
Date:10/3/2011

SAN DIEGO, Oct. 3, 2011 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), today announced that Contrave® (naltrexone SR/bupropion SR) data will be presented in one oral and multiple poster presentations at the 29th Annual Scientific Meeting of The Obesity Society on October 3, 2011 in Orlando, FL.  The Company will present results from evaluations of the COR (Contrave Obesity Research) program data for predicted long-term outcomes as well as responder analyses of Contrave treatment.  Additionally, Orexigen will present results of a recently completed clinical trial assessing the impact of Contrave on certain neurobiological mechanisms that control the brain's response to food cues.

A presentation led by Robert Chilton, DO, FACC, Professor of Medicine at the University of Texas Health Science Center at San Antonio, will discuss the impact of Contrave treatment on predicted 10-year cardiovascular (CV) outcomes as estimated using 1-year data from the Phase 3 COR program.  Multiple validated models utilizing different methodologies for evaluating CV risk were used to predict the long-term risk of CV disease, CV mortality, myocardial infarction and stroke with Contrave or placebo treatment.  A statistically significant three-fold reduction in predicted 10-year overall CV risk was observed with Contrave treatment compared to placebo.  These results are useful in predicting the potential impact of long-term treatment with Contrave and provide the Company with confidence in proceeding with the planned CV outcomes clinical trial.

"Weight loss results in improvements in cardiometabolic risk markers, and these data further corroborate the potential cardiovascular benefits of long term treatment with a weight loss therapy like Contrave," said Dr. Chilton." The consistency of the observations across the many risk equations utilize
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
2. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
3. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
4. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
5. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
6. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
7. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
8. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
9. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
10. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
11. Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... Md. , Aug. 4, 2015 ... drug-free over-the-counter ActiPatch® Musculoskeletal Pain Therapy medical devices, ... users of its ActiPatch 7-day trial device has ... journal Pain Management http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 .  ... the survey and submitted an assessment.  ...
(Date:8/4/2015)... 4, 2015 Research and Markets ( http://www.researchandmarkets.com/research/nl392k/alcohol ... Ethoxylate Market by Application (Household & Personal Care, Pharmaceutical, ... Forecasts to 2019" report to their offering. ... valued at $5,124.9 million in 2014 and is projected ... 2014 to 2019. The data mentioned in the report ...
(Date:8/4/2015)... Second Quarter 2015 Highlights: ... quarter of 2014 , Net earnings attributable to Team ... after adjustments , Diluted net earnings per share of ... 15.2% to $99.4 million 2015 Outlook: ... of 24.0% to 26.0%; Adjusted EBITDA margin remains between 10.5% ...
Breaking Medicine Technology:BioElectronics' Landmark 5,000+ Chronic Pain Patient Study Published in Pain Management Medical Journal 2Global Alcohol Ethoxylate Market 2015 - Market Trends, Forecasts to 2019 for the $5.1 Billion Industry 2Global Alcohol Ethoxylate Market 2015 - Market Trends, Forecasts to 2019 for the $5.1 Billion Industry 3Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 2Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 3Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 4Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 5Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 6Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 7Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 8Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 9Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 10Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 11Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 12Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 13Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 14Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 15Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 16Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 17Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 18Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 19Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 20Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 21Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 22Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 23Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 24Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 25Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 26Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 27Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 28Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 29Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 30Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 31Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 32Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 33
... Phase 2 Results of Perifosine in the Treatment of ... ... NEW YORK, June 2 Keryx Biopharmaceuticals,Inc. (Nasdaq: ... KRX-0401,(Perifosine) have been selected for both poster presentation and,publication ...
... June 2 Jazz,Pharmaceuticals, Inc. (Nasdaq: JAZZ ) ... Phase III pivotal clinical trials of JZP-6,(sodium oxybate) for ... this trial is a key milestone in the JZP-6,program. ... trial in the fourth,quarter of 2008," said Samuel Saks, ...
Cached Medicine Technology:Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois 2Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois 3Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois 4Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois 5Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia 2Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia 3
(Date:8/4/2015)... ... August 04, 2015 , ... PerceptiMed, ... Richard Carmona, M.D., M.P.H., FACS, to its Board of Directors effective August 1, ... lives," Dr. Carmona said. "I strongly believe in the mission of the company ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... Local Food,” scheduled for Nov. 3 – 4, 2015, at UC San Diego, ... create new businesses, improve food access, and manage resources efficiently against the dueling ...
(Date:8/4/2015)... ... ... Many men are confused about the safety of testosterone replacement therapy. In ... voice of authority for men seeking accurate information about testosterone. , Renew Man™ ... in the safe and effective treatment of low testosterone. In recent years, the experts ...
(Date:8/4/2015)... ... August 04, 2015 , ... They say a picture is worth a thousand ... and medical art can be essential. StayWell, a health solutions company, announced today it ... solutions have been used by physicians and other health care providers for more than ...
(Date:8/4/2015)... ... August 04, 2015 , ... Discovia, a leading ... announced that John Munro, a 15-year veteran of the eDiscovery services industry, has ... , “I am thrilled to join Discovia at this important point in its ...
Breaking Medicine News(10 mins):Health News:Dr. Richard Carmona, 17th Surgeon General of the United States, Joins PerceptiMed, Inc.’s Board of Directors 2Health News:Dr. Richard Carmona, 17th Surgeon General of the United States, Joins PerceptiMed, Inc.’s Board of Directors 3Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 2Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 3Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 2Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 3Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 2Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 3Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 2Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 3
... the sentencing of actor Sylvester Stallone came as an anti-climax ... Sydney. ,He was fined $2,975 for bringing banned ... of $10,000. ,A Customs search of his luggage ... February last had revealed 48 vials of the banned human ...
... of those suffering from AIDS came forth as hundreds of ... there to support them, gathered at a candlelight memorial ... AIDS Candlelight Memorial Day late Sunday saw more than 500 ... wearing white T-shirts and holding a candles. The third Sunday ...
... American bio-pharmaceutical major Gilead, which has entered into generic ... its HIV drug Viread, is hoping to get a ... made considerable progress in implementing our access programme and ... a pricing of $1 a day for the pill," ...
... According to a new study, repeated exposure to one person's ... shared opinions from multiple people. , ,This ... recipients sense of familiarity and in some cases gives a ... then it actually is. , ,In a series ...
... is on in the US to rein in sexual offenders ... safer for everyone. ,Social networking sites allow users ... and let them send messages to one another and, in ... MySpace had initially balked when attorneys general from eight states ...
... in the Shangdong province of eastern China have been afflicted ... has since been contained, state news agency Xinhua has reported. ... and another 393 people mostly children were still ... agency said, citing Bao Wenhui, the deputy director of the ...
Cached Medicine News:Health News:Steroid Scam: Sylvester Stallone Gets Away With a Light Punishment 2Health News:AIDS Victims, Supporters Gather in Bond of Hope 2Health News:Gilead's AIDS Drug Awaits Patent in India 2Health News:Repetition Is Like Chanting The More It is Heard the More You Believe It 2Health News:My Space Pressured into Sharing Data on Sex Offenders 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: